Effect of EGR1/LIPT1 regulatory axis on cuproptosis in chromophobe renal cell carcinoma.

阅读:3
作者:Luo Jingxian, Su Mingqiang, Li Xianyong, Ye Dayong, Zeng Xiaofu, Wang Yujie, Fu Guangqing
Renal cell carcinoma (RCC) is one of the most prevalent solid tumors, and chromophobe renal cell carcinoma (chRCC) is its third most common subtype. The cuproptosis has become a hot topic in the field of cancer treatment. This study aimed to investigate the potential targets of cuproptosis in chRCC cells. We first downloaded the chRCC mRNA transcriptome data from The Cancer Genome Atlas. Based on the previous reports, we speculated that the expression of LIPT1 was considerably down-regulated in chRCC tissues. The upstream transcription factor (TF) EGR1 was predicted by the hTFtarget web tool, and the interaction between EGR1 and LIPT1 was further verified by dual-luciferase and chromatin immunoprecipitation experiments. The mRNA expression levels of EGR1 and LIPT1 were detected by quantitative polymerase chain reaction. The expression levels of target protein LIPT1 and cuproptosis-associated protein were detected by western blot and immunofluorescence. Cell Counting Kit-8 assay was employed to detect the viability of RCC98 cells. The Transwell assay was utilized to assess the migration and invasion abilities of RCC98 cells. LIPT1 and its upstream TF, EGR1, were significantly down-regulated in chRCC tissues and cells. EGR1 could transcriptionally activate LIPT1. Additionally, overexpression of LIPT1 significantly reduced the cancer-associated malignant phenotype of chRCC and elevated the sensitivity of RCC98 cells to cuproptosis. However, on this basis, knocking down EGR1 restored the anti-cancer effect conferred by overexpression of LIPT1. This work aimed to investigate the transcriptional activation of LIPT1 by EGR1 in RCC98 cells to repress the malignant progression of cancer cells while enhancing the sensitivity of RCC98 cells to cuproptosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。